Effects of an Vitamin D on Neuropsychiatric Manifestations in Long COVID

Published: 5 February 2024| Version 1 | DOI: 10.17632/6w526j2dsn.1
Contributor:
Thammanard Charernboon

Description

This study aims to evaluate the effectiveness of high-dose vitamin D supplementation in alleviating fatigue, depression, anxiety, sleep problem and cognitive symptoms in patients with long COVID. The study is an 8-week, double-blind, randomized, placebo-controlled trial. Intervention is an vitamin D supplementation of 60,000 IU. Clinical outcomes were evaluated using the Chalder Fatigue Scale (CFQ-11), Depression, Anxiety, and Stress Scale-21 Items (DASS-21), Pittsburgh Sleep Quality Index (PSQI), Addenbrooke's Cognitive Examination III (ACE), and Trail Making Test A and B (TMT-A and TMT-B). Additionally, baseline and 8-week measurements of inflammatory markers, including Interleukin 6 (IL-6) and C-reactive protein (CRP), were collected.

Files

Institutions

Thammasat University

Categories

Medicine, Psychiatry, COVID-19

Licence